International Journal of Scientific Research and Modern Technology (IJSRMT) ijsrmt.com
Volume 2, Issue 8, 2023
DOI: https://doi.org/10.38124/ijsrmt.v2i8.462

Evaluating the Efficacy of Digital Therapeutics and Virtual Reality Interventions in Autism Spectrum Disorder Treatment

Paul Okugo Imoh[1]; Idoko Peter Idoko[2]

[1]School of Nursing, Anglia Ruskin University, Essex, United Kingdom
[2]Department of Biomedical Engineering, Faculty of Technology, University of Ibadan, Nigeria

Publication Date: 2023/08/28

Abstract
Autism Spectrum Disorder (ASD) is a multifactorial neurodevelopmental condition characterized by deficits in social communication, restricted interests, and behavioral rigidity. Traditional intervention paradigms, while foundational, often lack scalability, personalization, and cross-contextual generalizability. Recent advancements in digital health technologies—particularly Digital Therapeutics (DTx) and Virtual Reality (VR)—offer novel, computationally intelligent modalities for enhancing therapeutic outcomes in ASD populations. This review synthesizes current evidence on the efficacy, mechanisms, and clinical utility of DTx and VR in ASD treatment, with a focus on cognitive remediation, social-emotional learning, and adaptive behavior acquisition. DTx systems, delivered through mobile or web-based platforms, utilize algorithmic feedback loops, gamification mechanics, and behavioral analytics to support executive functioning and affective regulation. VR-based interventions, conversely, leverage immersive, multisensory simulations to replicate ecologically valid social scenarios, enabling targeted neurocognitive engagement. Comparative analyses reveal that while DTx offers scalability and high compliance, VR excels in embodied learning and social transferability. Hybrid therapeutic models integrating both modalities demonstrate enhanced adaptability and therapeutic efficacy through multimodal input fusion and real-time personalization. Despite promising outcomes, the field is constrained by gaps in longitudinal validation, standardization of outcome metrics, and ethical governance related to biometric data collection and algorithmic transparency. Future research must prioritize large-scale trials, AI-driven personalization engines, and cloud-based telehealth infrastructure. Additionally, interdisciplinary policy frameworks are imperative to ensure regulatory compliance, equitable access, and neurodevelopmentally appropriate content delivery. This review highlights the transformative potential of DTx and VR in advancing ASD care and advocates for their integration into evidence-based, digitally augmented treatment ecosystems.

Keywords: *Digital Therapeutics, Virtual Reality, Autism Spectrum Disorder, ASD Treatment, Efficacy Evaluation.*

I. INTRODUCTION

➢ *Background on Autism Spectrum Disorder (ASD)*

Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by persistent deficits in social communication and interaction, coupled with restricted, repetitive patterns of behavior, interests, or activities, as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (American Psychiatric Association, 2013). It manifests along a continuum of severity and symptom expression, necessitating individualized clinical approaches.

From a neurobiological perspective, ASD has been linked to atypical connectivity patterns in brain networks, particularly in the default mode network (DMN), salience network, and executive control systems, which contribute to impairments in social cognition, emotional regulation, and adaptive behavior (Uddin et al., 2013). Functional magnetic resonance imaging (fMRI) studies have revealed hypoconnectivity within long-range cortico-cortical tracts and hyperconnectivity in short-range circuits, implicating disruptions in synaptic pruning and neural plasticity during early development (Just et al., 2012).

Genomic studies suggest ASD has a polygenic architecture involving both rare de novo mutations and common inherited variants. Key genes implicated include *SHANK3*, *NRXN1*, and *CHD8*, which play roles in synaptogenesis and neuronal signaling (De Rubeis et al., 2014). Epigenetic modulation and environmental interactions, such as prenatal exposure to teratogens and immune dysregulation, also contribute to ASD pathogenesis (Lyall et al., 2014).

The global prevalence of ASD has shown a marked increase over the past two decades, with current estimates at approximately 1 in 54 children in the United States, based on CDC surveillance data (Maenner et al., 2020). While this rise partially reflects enhanced diagnostic practices and broader criteria, it underscores the urgent need for scalable, evidence-based therapeutic interventions.

ASD's heterogeneity in phenotype and comorbid conditions—including intellectual disability, epilepsy, attention-deficit/hyperactivity disorder (ADHD), and anxiety disorders—further complicates diagnosis and treatment, emphasizing the demand for personalized and technologically enhanced therapeutic modalities (Lai et al., 2014).

Figure 1 illustrates the complex roots contributing to the rising prevalence and clinical complexity of Autism Spectrum Disorder (ASD). Depicted as a tree, it highlights six key factors—genetic, neurobiological, diagnostic, environmental, and phenotypic—that interact to shape ASD manifestation. Understanding these interconnected influences is crucial for improving diagnosis, treatment, and research efforts.



Fig 1 Increasing Autism Spectrum Disorder (ASD) Prevalence

- *Traditional Treatment Approaches for ASD*

Conventional interventions for Autism Spectrum Disorder (ASD) have historically centered on behavioral, developmental, and pharmacological approaches aimed at improving functional outcomes and mitigating maladaptive behaviors. Among the most widely adopted modalities is Applied Behavior Analysis (ABA), a data-driven technique grounded in operant conditioning principles, which employs discrete trial training (DTT), natural environment teaching (NET), and task analysis to promote adaptive skills acquisition (Lovaas, 1987; Leaf et al., 2016). ABA has demonstrated efficacy in enhancing language, cognitive functioning, and daily living skills, particularly when implemented intensively (≥30 hours/week) and initiated during early developmental windows.

Developmental interventions such as the Early Start Denver Model (ESDM) integrate ABA principles with play-based, relationship-focused strategies to stimulate social engagement and communication in toddlers with ASD. Neuroimaging studies have shown that children undergoing ESDM exhibit normalized activation in prefrontal and temporal cortical regions associated with social processing, suggesting experience-dependent neuroplasticity (Dawson et al., 2012).

Pharmacotherapy for ASD does not target core social-communicative deficits directly but is utilized to manage comorbid symptoms such as irritability, aggression, and hyperactivity. Atypical antipsychotics like risperidone and aripiprazole are FDA-approved for irritability in ASD and exert their effects through dopaminergic (D2) and serotonergic (5-HT2A) receptor modulation (McPheeters et al., 2011). However, adverse effects, including weight gain and extrapyramidal symptoms, pose significant concerns for long-term use (Volkmar et al., 2014).

Speech and language therapy, often paired with augmentative and alternative communication (AAC) tools such as Picture Exchange Communication Systems (PECS), has also shown moderate success in supporting expressive and receptive language development. However, outcomes are heterogeneous and often influenced by baseline cognitive function and the presence of comorbid apraxia of speech (Schlosser & Wendt, 2008).

Despite the diversity of traditional interventions, limitations remain in generalizability, scalability, and personalization. Additionally, many of these therapies are labor-intensive and require trained specialists, which limits accessibility in low-resource settings. These constraints underscore the need for technologically mediated approaches capable of enhancing engagement and ensuring continuity of care in diverse populations.

- *Emergence of Digital Health Innovations*

The integration of digital health technologies in neurodevelopmental care has emerged as a transformative force in augmenting traditional therapeutic modalities for Autism Spectrum Disorder (ASD). Among these, Digital Therapeutics (DTx) and Virtual Reality (VR) represent two of the most disruptive innovations in precision neuropsychiatry, leveraging software-driven interventions to target cognitive, behavioral, and social deficits with high specificity and scalability (Hollis et al., 2017). DTx platforms utilize evidence-based algorithms embedded in mobile or web-based environments to deliver structured therapy, often with real-time feedback and adaptive learning protocols guided by artificial intelligence (Torous et al., 2019).

Virtual Reality, characterized by immersive human–computer interaction via multisensory environments, has proven effective in simulating complex social scenarios that are otherwise difficult to replicate in clinical or home settings. These VR systems activate brain regions implicated in social processing—such as the medial prefrontal cortex, amygdala, and temporoparietal junction—facilitating targeted neuroplasticity in ASD populations (Keshav et al., 2017). Several studies using head-mounted display (HMD)-based VR have reported significant improvements in emotion recognition, eye gaze coordination, and situational social skills in children and adolescents with ASD (Kandalaft et al., 2013).

The convergence of machine learning (ML) and digital phenotyping in DTx platforms further enables passive behavioral monitoring and personalized intervention through continuous analysis of multimodal data streams such as facial affect, speech prosody, and touchscreen interaction metrics (Insel, 2017). These advancements support the development of dynamic, context-aware therapeutic systems that evolve with the user's behavioral state, ensuring treatment alignment with moment-to-moment cognitive and emotional needs.

Importantly, digital platforms can overcome geographic and socioeconomic barriers by providing remote, asynchronous intervention delivery, a feature that became particularly vital during the COVID-19 pandemic (Dahiya et al., 2021). However, successful deployment of these tools requires rigorous validation through randomized controlled trials (RCTs), regulatory oversight by bodies such as the FDA for software-as-a-medical-device (SaMD), and long-term user engagement strategies to mitigate attrition.

II. DIGITAL THERAPEUTICS (DTX) IN ASD MANAGEMENT

- *Conceptual Framework and Mechanisms of Digital Therapeutics (DTx)*

Digital Therapeutics (DTx) constitute a distinct subset of digital health interventions that deliver evidence-based therapeutic interventions to patients through high-quality software programs, with the objective of preventing, managing, or treating a medical disorder or disease (Raspa et al., 2020). Unlike general wellness applications, DTx are designed in accordance with rigorous clinical protocols, often validated through randomized controlled trials (RCTs), and can be prescribed adjunctively or as standalone treatments.

The theoretical basis for DTx in Autism Spectrum Disorder (ASD) draws upon principles from cognitive-behavioral theory, computational psychiatry, and neurodevelopmental modeling, operationalized through interactive digital platforms. These platforms integrate machine learning algorithms, digital biomarkers, and user-centered design to dynamically personalize interventions in real time (Topol, 2019). Central to their architecture is the use of closed-loop systems, where patient interactions inform algorithmic adjustments that optimize therapeutic outcomes through feedback loops—a process akin to reinforcement learning paradigms used in behavioral psychology (Zhao et al., 2021).

Neuroscientifically, DTx aim to influence underlying cortico-striatal-thalamic circuits associated with social cognition, executive function, and affect regulation—domains frequently impaired in ASD (Eack et al., 2013). These interventions leverage structured digital environments to present adaptive challenges that stimulate neuroplasticity, thereby supporting the functional reorganization of targeted neural substrates. For instance, gamified DTx modules have been shown to enhance working memory and response inhibition by repeatedly engaging prefrontal cortical circuits via sustained attention tasks and inhibitory control training (Anguera et al., 2013).

In ASD-specific applications, DTx systems often utilize multimodal data inputs—including gaze tracking, voice modulation, facial affect recognition, and touchscreen kinematics—to monitor behavioral phenotypes and modulate content delivery accordingly (Naslund et al., 2020). This real-time phenotyping facilitates precision intervention, allowing DTx platforms to accommodate intra-individual variability and contextual nuances that often challenge traditional interventions.

Digital Therapeutics (DTx) represent a clinically validated subset of digital health tools designed to treat or manage medical conditions through software-driven interventions. In Autism Spectrum Disorder (ASD), DTx harness neurodevelopmental modeling and machine learning to deliver real-time, personalized care. Table 1 below summarizes the conceptual framework and mechanisms underpinning the application of DTx in ASD.

Table 1 Framework and Mechanisms of Digital Therapeutics in Autism Spectrum Disorder (ASD)

Dimension	Description	Mechanism of Action	Clinical Focus in ASD	Example/Insight
Theoretical Foundation	Based on cognitive-behavioral theory, computational psychiatry, and neurodevelopmental modeling	Algorithmic personalization and feedback loops	Enhancing executive function, social cognition, and emotion regulation	Reinforcement learning paradigms guide dynamic interaction adjustments
Technological Integration	Incorporates machine learning, digital biomarkers, and user-centered design	Closed-loop systems for real-time therapy optimization	Tailors interventions to individual traits and behaviors	Digital platforms adapt content based on gaze, voice, or facial expression data
Neuroscientific Targeting	Engages cortico-striatal-thalamic circuits linked to key cognitive domains	Stimulates neuroplasticity through structured, repetitive challenges	Improves working memory, inhibitory control, and attentional regulation	Gamified DTx modules train prefrontal cortex functions
Behavioral Monitoring	Uses multimodal data inputs for continuous behavioral phenotyping	Real-time feedback informs adaptive therapeutic content	Accommodates intra-individual variability and real-world contextual changes	Eye tracking, speech analysis, and gesture recognition refine precision care
Regulatory Validation	Guided by FDA's Software as a Medical Device (SaMD) framework	Clinically recognized software with therapeutic claims	Validates DTx for ASD within healthcare frameworks	FDA approval underscores credibility of DTx for psychiatric and neurodevelopmental disorders

Furthermore, regulatory frameworks have begun adapting to the unique classification of DTx. The U.S. Food and Drug Administration (FDA) has provided guidance on Software as a Medical Device (SaMD), acknowledging the therapeutic potential of algorithmically driven platforms, especially in neurodevelopmental and psychiatric disorders (FDA, 2019). These evolving standards underscore the clinical legitimacy and expanding integration of DTx within mainstream healthcare delivery systems.

➢ *Review of Evidence-Based DTx Applications in ASD*

Digital therapeutics (DTx) for Autism Spectrum Disorder (ASD) have evolved into targeted, evidence-based interventions that operationalize cognitive and behavioral modification through algorithmically controlled therapeutic environments. A growing body of randomized controlled trials and longitudinal feasibility studies support the clinical utility of these tools in enhancing core and associated symptoms in ASD, including deficits in social communication, emotional regulation, and executive function (Whitehouse et al., 2017).

One prominent DTx innovation is the Empowered Brain system, a wearable device integrated with smartglasses technology that delivers social-emotional coaching using real-time facial emotion recognition and gaze tracking. By delivering micro-interventions through augmented reality overlays, the system activates the fusiform face area and dorsomedial prefrontal cortex, regions implicated in social cognition, thus demonstrating neurobiological relevance (Sahin et al., 2018). Pilot trials revealed significant improvements in attention to social cues and reductions in hyperactivity, suggesting its dual utility in ASD with comorbid ADHD (Vahabzadeh et al., 2016).

Another validated DTx tool is the TOBY (Therapy Outcomes by You) application, which offers over 300 structured learning tasks across language, cognitive, and sensory domains, rooted in ABA principles and delivered via an interactive tablet interface. In clinical settings, TOBY has been associated with measurable improvements in joint attention and expressive communication when used as an adjunct to therapist-led interventions (Whitehouse et al., 2017).

Gamified DTx platforms such as FaceSay and MeCue focus on emotion recognition, theory of mind, and reciprocal interaction by leveraging repetitive gameplay mechanics that reinforce social-emotional learning (Hopkins et al., 2011). These systems often employ adaptive difficulty levels and multimodal feedback (visual-auditory-haptic) to optimize engagement while targeting neural systems involved in affective empathy and mirror neuron activation.

Additionally, software like MindReading: The Interactive Guide to Emotions has shown promise in teaching individuals with high-functioning ASD to interpret complex facial expressions by using real-life video footage annotated with emotion labels and contextual cues. Neuropsychological testing post-intervention indicates enhanced performance on Reading the Mind in the Eyes Test (RMET) and increased social motivation scores (Golan et al., 2010).

Despite these advancements, real-world scalability remains limited due to variability in user adherence, disparities in digital literacy among caregivers, and limited reimbursement models. However, the demonstrated efficacy across cognitive-behavioral metrics affirms the viability of DTx as a therapeutic adjunct in ASD management, particularly in hybrid or telehealth-enabled care models (Ramirez et al., 2020).

Figure 2 showcases digital therapeutic solutions designed to support individuals with Autism Spectrum Disorder (ASD). It highlights innovative tools like the Empowered Brain System, TOBY Application, gamified platforms, and MindReading software, which target specific ASD symptoms. The illustration also acknowledges scalability challenges, emphasizing the need for accessible and sustainable implementation.



Fig 2 Exploring Digital Therapeutics for ASD

➢ *Challenges and Limitations of DTx in ASD*

Despite the increasing clinical interest and evidence supporting digital therapeutics (DTx) for Autism Spectrum Disorder (ASD), numerous barriers limit their widespread adoption, long-term efficacy, and equitable implementation. One of the primary challenges is interindividual variability in treatment response, often linked to heterogeneity in ASD phenotypes, cognitive profiles, and comorbidities. Current DTx systems, although algorithmically adaptive, may lack the neurocognitive flexibility required to dynamically respond to the complex, non-linear progression of symptoms in individuals with moderate to severe ASD (Lindgren et al., 2016).

User engagement and adherence remain significant issues, particularly in pediatric populations with attentional deficits or sensory processing dysfunctions. Studies have demonstrated that drop-off rates in DTx usage can exceed 40% over four weeks, particularly when content lacks affective personalization or gamification elements necessary to sustain motivation (Baumel et al., 2019). Moreover, children with ASD often display strong preferences or aversions to specific stimuli, which can lead to underutilization or aversive behavioral responses when sensory features of DTx (e.g., sound, color, haptic feedback) are poorly optimized (Parsons et al., 2017).

Another technical limitation is the incomplete integration of real-time biosignal monitoring, such as heart rate variability (HRV), galvanic skin response (GSR), and EEG-based attention indices, which are critical for developing closed-loop neuroadaptive systems. Without physiological feedback mechanisms, many current DTx models function in open-loop architectures, constraining their ability to modulate intervention intensity based on neurophysiological states (Sahin et al., 2018).

Digital divide and accessibility inequities further exacerbate implementation challenges. Families in low-income or rural settings frequently lack access to high-speed internet, compatible hardware, or technical literacy to support DTx deployment (Ramirez et al., 2020). This digital inequity undermines the scalability and inclusiveness of these interventions, particularly in global health contexts.

While Digital Therapeutics (DTx) offer promising avenues for Autism Spectrum Disorder (ASD) treatment, their integration into real-world care faces substantial challenges. These barriers span technical, behavioral, infrastructural, and regulatory domains. Table 2 below summarizes key limitations affecting the efficacy, accessibility, and sustainability of DTx interventions for ASD.

Table 2 Barriers to the Adoption and Efficacy of Digital Therapeutics in Autism Spectrum Disorder (ASD)

Barrier Category	Description	Underlying Cause	Implications for ASD Treatment	Supporting Evidence
Patient-Level Variability	High heterogeneity in ASD symptomatology, cognitive capacity, and comorbidities affects DTx responsiveness	Limited neuroadaptive flexibility in current DTx systems	Inconsistent treatment outcomes, especially in moderate to severe ASD	Lindgren et al., 2016
Engagement and Adherence	Low sustained usage due to attentional deficits and poorly personalized content	Lack of gamification, emotional responsiveness, or sensory adaptability	Dropout rates over 40% limit long-term effectiveness	Baumel et al., 2019; Parsons et al., 2017
Technical Limitations	Absence of real-time biosignal integration reduces adaptiveness of therapeutic loops	Lack of HRV, GSR, or EEG feedback prevents closed-loop neuroadaptive control	DTx platforms remain static and less responsive to moment-to-moment patient states	Sahin et al., 2018
Digital Access Inequity	Limited access to devices, internet, and digital literacy in underserved populations	Socioeconomic and geographic disparities	Hinders equitable deployment and scalability of DTx interventions globally	Ramirez et al., 2020
Regulatory and Ethical Gaps	Data privacy concerns and lack of standardization in clinical validation hamper clinical trust	Incomplete HIPAA/GDPR compliance, unclear regulatory pathways	Slows approval, limits adoption by clinicians and institutions	Torous et al., 2019

From a regulatory and ethical standpoint, there is ongoing debate surrounding data privacy, algorithmic transparency, and clinical oversight in DTx platforms. Most systems collect extensive behavioral and biometric data, yet only a subset are compliant with HIPAA or GDPR frameworks, raising significant concerns over informed consent and data protection (Torous et al., 2019). Additionally, the lack of standardized outcome metrics and regulatory pathways complicates cross-comparability across DTx systems and delays clinical endorsement.

III. VIRTUAL REALITY (VR) INTERVENTIONS IN ASD

- *Overview of VR Technologies Used in ASD Therapy*

Virtual Reality (VR) has emerged as a sophisticated technological modality for augmenting therapeutic interventions in individuals with Autism Spectrum Disorder (ASD), offering controlled, immersive environments for targeted neurocognitive training. VR systems are typically categorized into non-immersive, semi-immersive, and fully immersive platforms, each varying in sensory fidelity and levels of user embodiment (Parsons & Cobb, 2011). Fully immersive VR, often facilitated through Head-Mounted Displays (HMDs), provides multisensory simulations that can closely mimic real-world social and environmental interactions while maintaining the safety and customizability necessary for individuals with ASD who may experience sensory hypersensitivity (Maskey et al., 2014).

The fundamental advantage of VR in ASD therapy lies in its ability to offer ecologically valid, yet repeatable, social scenarios for training interpersonal skills, such as recognizing facial expressions, understanding conversational norms, and practicing theory of mind. These environments can be finely tuned to control for confounding stimuli, an essential feature for individuals with impaired sensory integration and attentional modulation (Kandalaft et al., 2013). VR platforms often incorporate real-time biometric feedback mechanisms—such as eye-tracking, galvanic skin response (GSR), and motion capture—to quantify user engagement, affective responses, and behavioral outcomes (Ke & Im, 2013).

Contemporary VR applications in ASD span both desktop-based systems (e.g., virtual avatars on PC platforms) and mobile VR using lightweight devices like Oculus Quest or Google Cardboard, with software developed using engines like Unity or Unreal. These systems often deploy embodied agents or avatars equipped with AI-driven social cues to facilitate joint attention, emotional inference, and prosocial reinforcement. For instance, multi-user VR systems allow for real-time social interactions between peers or therapists and users in virtual environments, thus enabling synchronous communication modeling and feedback (Lorenzo et al., 2016).

Moreover, advances in affective computing and natural language processing are increasingly integrated into VR platforms to enable dynamic dialogue generation and sentiment analysis. This further enhances the realism of therapeutic scenarios and facilitates adaptive progression of difficulty levels based on user performance metrics (Parsons, 2016).

Virtual Reality (VR) technologies are increasingly being adopted as innovative tools for therapeutic interventions in Autism Spectrum Disorder (ASD). These immersive and semi-immersive systems provide controlled, repeatable environments ideal for neurocognitive and social training. Table 3 below outlines key classifications, components, and therapeutic mechanisms of VR used in ASD treatment.

Table 3 Classification and Mechanisms of Virtual Reality Applications in Autism Spectrum Disorder (ASD) Therapy

VR Category	Description	Therapeutic Mechanism	Technological Components	Application Insight
Non-Immersive VR	Desktop-based systems with limited sensory immersion	Avatar-guided behavioral modeling, emotion recognition	PC display, keyboard/mouse, basic sensors	Used for initial social skills training and cognitive engagement
Semi-Immersive VR	Projects partial environments with moderate sensory input	Controlled exposure to social stimuli, gradual desensitization	Large screen displays, motion tracking cameras	Helps users transition into more immersive experiences safely
Fully Immersive VR	Engages multiple senses through HMDs and motion tracking	Embodied simulations for real-life social scenario rehearsal	Head-Mounted Displays (e.g., Oculus), haptic controllers, 360° environments	Allows safe, repeatable practice of theory of mind and emotion regulation
Real-Time Biometric Feedback VR	Uses physiological inputs to modulate and adapt scenarios	Tracks engagement and stress levels to adjust difficulty	Eye-tracking, GSR sensors, motion capture, AI analytics	Facilitates personalized intervention and enhances user attention
Cloud-Integrated VR Systems	Enables remote therapy delivery and behavioral data collection	Supports telehealth, long-term modeling, and cross-contextual generalization	Cloud-based LMS, remote therapist access, NLP modules, affective computing engines	Enhances scalability and treatment consistency across diverse environments

Importantly, VR-based ASD interventions are increasingly being incorporated into telehealth infrastructure and cloud-based learning management systems, facilitating remote monitoring and cross-contextual data collection—key for long-term behavioral modeling and generalized skill transfer (Lorenzo et al., 2016). Despite high upfront technological requirements, these systems demonstrate promise in enhancing treatment fidelity and enabling scalable therapeutic delivery.

➢ *Clinical Outcomes of VR-Based ASD Interventions*

Virtual Reality (VR)-based interventions have demonstrated promising efficacy in improving core and associated symptomatology in individuals with Autism Spectrum Disorder (ASD), with particular effectiveness observed in domains of social cognition, emotional regulation, and anxiety modulation. Controlled trials and neuropsychological studies report that VR-enhanced training protocols significantly improve facial emotion recognition, eye-contact maintenance, and reciprocal communication skills, particularly in children and adolescents with high-functioning ASD (Kandalaft et al., 2013).

Neurocognitive mechanisms underlying these improvements involve modulation of activity in the amygdala, superior temporal sulcus, and medial prefrontal cortex—regions essential for socio-emotional processing. Functional MRI data post-VR training reveal increased functional connectivity in social cognition networks and enhanced neuroadaptive plasticity, supporting the hypothesis that VR can serve as a scaffold for real-world generalization of learned behaviors (Miller & Bugnariu, 2016).

In clinical studies utilizing immersive HMD-based platforms, participants demonstrated statistically significant gains in joint attention, theory of mind, and contextual language use, assessed through standardized instruments such as the Social Responsiveness Scale (SRS-2) and Autism Diagnostic Observation Schedule (ADOS-2) (Lorenzo et al., 2016). These outcomes are often augmented by the integration of eye-tracking and physiological monitoring, which allow for objective measurement of attention allocation and arousal regulation during social simulations (Ke & Moon, 2018).

Additionally, VR has shown robust results in reducing specific phobias and situational anxiety common in ASD populations. Exposure-based VR protocols have been particularly successful in desensitizing individuals to anxiety-inducing scenarios such as public speaking, classroom environments, or public transportation, by engaging the limbic-hypothalamic circuits in a controlled, repeatable manner (Maskey et al., 2019). Such VR-based exposure therapies often produce durable effects, with follow-up evaluations indicating symptom attenuation sustained over several months post-intervention.

Importantly, the ecological validity of VR training has been supported by case studies and meta-analyses suggesting positive behavioral transfer to naturalistic settings, such as classrooms and home environments, particularly when VR modules are combined with therapist feedback or caregiver reinforcement strategies (Parsons & Cobb, 2011). This generalization potential, coupled with high user acceptability and low dropout rates, positions VR as a scalable and efficacious adjunct to conventional ASD therapies.

Figure 3 presents a balanced overview of the pros and cons of using digital tools, particularly virtual reality (VR), in Autism Spectrum Disorder (ASD) interventions. It outlines key benefits such as improved social skills, enhanced brain function, and high user acceptance, alongside challenges like cost, technical issues, and lack of long-term data. The visual underscores the need for innovation while addressing barriers to broader clinical implementation.



Fig 3 VR for ASD

➢ *Barriers to VR Adoption in ASD Treatment*

Despite the demonstrated efficacy of Virtual Reality (VR)-based interventions in Autism Spectrum Disorder (ASD) treatment, several barriers—technological, physiological, socioeconomic, and infrastructural—continue to constrain large-scale clinical implementation. A critical concern involves sensory sensitivities and cybersickness, which are prevalent in ASD populations and may be exacerbated by immersive VR environments. The motion-to-photon latency inherent in head-mounted displays (HMDs), often exceeding 20 milliseconds, can disrupt sensorimotor synchrony and provoke symptoms such as dizziness, nausea, and ocular strain, especially in users with impaired vestibular processing (Miller & Bugnariu, 2016).

Cognitive overload and limited attentional bandwidth also restrict the therapeutic utility of VR in individuals with intellectual impairments or concurrent ADHD. High-fidelity simulations, while rich in ecological validity, may overwhelm executive processing capacities, leading to task disengagement or behavioral dysregulation (Newbutt et al., 2016). Consequently, calibration of environmental complexity and multimodal feedback must be tailored to individual cognitive profiles to optimize intervention fidelity.

Moreover, cost and accessibility of VR hardware remain significant barriers to adoption in resource-constrained settings. Advanced VR systems—particularly those utilizing six degrees of freedom (6DoF) tracking and eye-tracking integration—often exceed the budgetary capabilities of educational and clinical institutions, particularly in low- and middle-income countries (Parsons & Cobb, 2011). In addition, limited availability of trained personnel to configure, deploy, and troubleshoot these systems exacerbates implementation inertia, especially outside urban research hubs.

Another challenge pertains to the lack of standardized VR protocols and outcome measures, which hinders cross-study comparability and meta-analytic synthesis. Unlike traditional therapies anchored in established diagnostic and therapeutic frameworks (e.g., DSM-5, ADOS-2), VR interventions often vary widely in content design, duration, and behavioral metrics, making it difficult to generalize results or secure regulatory approval for therapeutic claims (Riva et al., 2016). The absence of universally accepted clinical endpoints and reproducible paradigms contributes to skepticism among practitioners and policymakers.

While Virtual Reality (VR) presents a transformative opportunity in Autism Spectrum Disorder (ASD) therapy, multiple adoption barriers limit its scalability and clinical integration. These challenges span physiological tolerance, cognitive adaptability, infrastructure constraints, and regulatory ethics. Table 4 below identifies and explains the major categories of barriers affecting the widespread implementation of VR in ASD treatment.

Table 4 Barriers to Virtual Reality Adoption in Autism Spectrum Disorder (ASD) Therapy

Barrier Type	**Description**	**Primary Cause**	**Therapeutic Impact**	**Supporting Source**
Sensory and Physiological Limitations	Immersive VR can trigger cybersickness and sensory overstimulation in ASD users due to vestibular dysfunction and motion-to-photon latency	Latency in HMDs, impaired sensorimotor integration	Causes nausea, dizziness, and reduces tolerability of sessions	Miller & Bugnariu, 2016
Cognitive Load and Attentional Constraints	Complex simulations may exceed cognitive bandwidth, especially in users with ADHD or intellectual disability	Overloaded executive function, poor attentional regulation	Leads to disengagement, behavioral dysregulation, and therapy dropout	Newbutt et al., 2016
Economic and Infrastructural Access	High costs of VR systems and lack of trained personnel limit feasibility in clinical or educational settings	Expensive hardware (e.g., 6DoF systems), rural or low-resource environments	Limits adoption in underserved regions, widens treatment gaps	Parsons & Cobb, 2011
Lack of Standardized Protocols	Absence of uniform intervention models, outcome metrics, and therapeutic frameworks impedes evidence generalization	Inconsistent content, varied session duration, diverse behavioral metrics	Hinders clinical validation and regulatory approval	Riva et al., 2016
Ethical and Data Privacy Concerns	Use of biometric data and avatars raises concerns around informed consent, data protection, and ethical transparency, especially in children	Limited HIPAA/GDPR compliance, real-time behavioral data collection	Erodes trust, poses risks of misuse or exploitation	Torous et al., 2019

Finally, data security and ethical governance are growing concerns as VR platforms increasingly collect biometric and behavioral data streams, including gaze fixation, speech patterns, and emotional expressions. While such data provide rich analytic value for personalizing therapy, their storage and processing raise concerns about HIPAA and GDPR compliance, particularly in pediatric populations (Torous et al., 2019). The ethical use of avatars, simulated agents, and real-time interaction logs necessitates rigorous data governance frameworks to protect vulnerable users from exploitation and ensure informed consent is meaningfully obtained.

IV. COMPARATIVE EVALUATION AND INTEGRATION STRATEGIES

➢ *DTx vs. VR: Efficacy, Engagement, and Outcomes*

Comparative evaluations of Digital Therapeutics (DTx) and Virtual Reality (VR) in Autism Spectrum Disorder (ASD) interventions reveal distinct strengths and limitations across efficacy, user engagement, and therapeutic outcomes. While both modalities harness digital innovation to support behavioral and cognitive rehabilitation, their underlying mechanisms, target domains, and modes of user interaction differ substantially, yielding complementary but non-redundant clinical utilities.

DTx platforms, typically deployed through mobile or tablet-based applications, offer high accessibility, portability, and algorithmic personalization. Their strength lies in delivering repetitive, structured, and data-driven interventions targeting specific cognitive functions such as working memory, attention modulation, and emotion labeling (Raspa et al., 2020). These systems frequently utilize real-time feedback loops and adapt their content using machine learning models, thus providing longitudinal tracking of user behavior and enabling dynamic response to performance metrics (Topol, 2019). However, the inherently two-dimensional and screen-bound nature of DTx may limit its effectiveness in replicating complex, context-dependent social environments.

In contrast, VR excels in delivering immersive, embodied simulations that facilitate social cognition training through exposure to virtual environments that mirror real-world interpersonal interactions. VR-based therapies leverage sensorimotor integration, spatial presence, and avatar-mediated communication to enhance joint attention, theory of mind, and nonverbal communication skills (Kandalaft et al., 2013). Empirical findings demonstrate that VR interventions result in increased engagement due to their gamified and interactive nature, particularly among individuals with high-functioning ASD, who often show elevated motivation for technology-based tasks (Lorenzo et al., 2016).

In terms of clinical efficacy, DTx has been associated with moderate improvements in executive function and emotion recognition tasks when assessed using standardized neuropsychological tools such as the Behavior Rating Inventory of Executive Function (BRIEF) and the Social Communication Questionnaire (SCQ) (Whitehouse et al., 2017). Meanwhile, VR studies have reported gains in dynamic social skill acquisition, with transfer effects observed in naturalistic environments, including classrooms and group therapy settings—an outcome less consistently demonstrated with conventional DTx (Ke & Im, 2013).

Nevertheless, engagement duration and cognitive load must be carefully considered. DTx applications tend to be better tolerated over prolonged use, with fewer reports of sensory fatigue or cybersickness. In contrast, although VR systems show higher initial engagement, they may induce sensory overstimulation or motion sickness in sensitive users, particularly those with vestibular instability or attention regulation deficits (Miller & Bugnariu, 2016).

In sum, DTx offers a scalable, metrics-rich intervention ideal for cognitive training and asynchronous use, while VR provides ecologically valid simulations critical for advancing real-world social functioning. The two modalities, when combined, offer a synergistic framework for personalized, multi-domain therapeutic intervention in ASD care.

Figure 4 evaluates the trade-offs between clinical efficacy and user engagement in digital therapeutics (DTx) and virtual reality (VR) applications for Autism Spectrum Disorder (ASD). It contrasts high-efficacy but low-engagement cognitive training with highly engaging VR tools that may induce motion sickness or sensory fatigue. The visual highlights the need to balance therapeutic impact with usability in digital ASD interventions.



Fig 4 Comparative Analysis of DTx and VR in ASD Interventions

- *Hybrid Models and Multimodal Therapeutic Approaches*

The convergence of Digital Therapeutics (DTx) and Virtual Reality (VR) within hybrid intervention frameworks represents an emergent paradigm in Autism Spectrum Disorder (ASD) treatment, capitalizing on the complementary strengths of both modalities. These multimodal therapeutic architectures are designed to integrate cognitive remediation strategies embedded in DTx platforms with the immersive, ecologically valid simulations offered by VR, enabling a more holistic and scalable treatment model (Smith et al., 2020).

Hybrid systems often utilize DTx modules for foundational skill acquisition, such as emotion labeling, executive functioning tasks, and language processing, followed by VR simulations that place those learned skills in dynamic social contexts (Parsons & Cobb, 2011). For instance, a patient may first engage in mobile-based emotion recognition exercises using a DTx app and then transition into a VR scenario involving a simulated classroom where the correct application of those emotional inferences is required. This sequential training pipeline facilitates both skill consolidation and contextual generalization, a persistent limitation in single-modality therapies (Riva et al., 2016).

Moreover, hybrid models benefit from the integration of biometric sensors, such as EEG headbands, eye trackers, and galvanic skin response (GSR) devices, to monitor cognitive workload, attentional engagement, and affective arousal. These data streams can feed into machine learning algorithms embedded in the DTx component to adjust task difficulty and into VR engines to modulate environmental parameters like lighting, auditory complexity, or social density, thereby maintaining optimal therapeutic engagement zones (Lorenzo et al., 2016).

Pilot studies exploring such integrations have shown that telepresence-supported DTx-VR hybrids increase therapeutic adherence, improve outcomes in social responsiveness (as measured by the SRS-2), and demonstrate sustained behavioral gains post-treatment (Keshav et al., 2017). Additionally, when combined with therapist-mediated feedback, these systems promote closed-loop learning environments where human and algorithmic insights are synchronized to personalize care.

However, the successful deployment of hybrid systems requires addressing technical interoperability, ensuring that software frameworks (e.g., Unity3D for VR and Python/TensorFlow for DTx) can operate seamlessly and synchronize patient data through secure cloud infrastructures. Furthermore, training clinicians to interpret multidimensional data outputs from both systems and integrate them into evidence-based clinical decisions remains a critical step toward operational scalability (Insel, 2017).

Hybrid therapeutic systems that integrate Digital Therapeutics (DTx) and Virtual Reality (VR) are reshaping Autism Spectrum Disorder (ASD) intervention strategies. These multimodal models combine cognitive training with immersive environments to improve skill generalization, engagement, and long-term behavioral outcomes. Table 5 below outlines the structural components, benefits, and challenges of these hybrid approaches in ASD therapy.

Table 5 Hybrid DTx-VR Models for Autism Spectrum Disorder: Structure, Benefits, and Implementation Challenges

Hybrid Component	Functional Description	Therapeutic Synergy	Technical Enabler	Evidence/Application
Sequential Integration	Combines DTx for foundational training (e.g., emotion recognition) with VR for contextual application (e.g., social simulations)	Facilitates skill transfer from controlled settings to dynamic real-world scenarios	Cross-platform architecture linking mobile apps with VR environments (e.g., Unity3D, Unreal)	Parsons & Cobb, 2011; Riva et al., 2016
Biometric Feedback Loop	Monitors engagement and emotional arousal via EEG, GSR, and eye-tracking	Enables real-time adaptation of difficulty and sensory load across both modalities	Embedded sensors and ML algorithms to regulate intervention fidelity	Lorenzo et al., 2016
Therapist-AI Collaboration	Therapist provides feedback while algorithms personalize interventions based on biometric and behavioral data	Promotes closed-loop learning and individualized trajectories	Cloud-based platforms integrating clinician dashboards with AI-driven data models	Keshav et al., 2017
Outcome Measurement	Uses validated tools like SRS-2 and behavioral logs to assess intervention effectiveness	Tracks both in-session performance and post-treatment behavioral maintenance	Integrated assessment modules synchronized across DTx and VR environments	Smith et al., 2020
Interoperability Challenge	Synchronizing DTx (e.g., TensorFlow-based) with VR platforms (e.g., Unity3D) and clinician workflows	Ensures seamless data flow and unified patient experience	Middleware APIs, secure cloud storage, and clinician training on multidimensional analytics	Insel, 2017

Ultimately, hybridized therapeutic ecosystems have the potential to redefine ASD intervention by fusing real-time analytics, immersive simulation, and cognitive scaffolding, making them particularly suited for individualized neurodevelopmental trajectories and cross-context behavioral transfer.

➢ *Ethical, Cultural, and Developmental Considerations*

The deployment of Digital Therapeutics (DTx) and Virtual Reality (VR) in Autism Spectrum Disorder (ASD) treatment introduces a complex array of ethical, cultural, and developmental considerations that must be rigorously addressed to ensure equitable, safe, and developmentally appropriate therapeutic outcomes. As these technologies increasingly intersect with neurodiverse populations—many of whom are children or individuals with impaired decision-making capacity—the imperatives for informed consent, data privacy, and cultural competence become central to their design and implementation (Torous et al., 2019).

From an ethical standpoint, DTx and VR systems often involve continuous, real-time behavioral data acquisition—including eye gaze, emotional expression, speech patterns, and physiological signals—raising concerns regarding biometric surveillance and algorithmic bias. In pediatric and adolescent ASD populations, the legitimacy of proxy consent and the extent to which minors understand the implications of data usage pose significant challenges, particularly when machine learning algorithms are used in diagnostic prediction or behavior monitoring without transparency (Insel, 2017).

Culturally, the content and context of therapeutic scenarios embedded in VR or DTx platforms may not reflect the linguistic, social, or environmental norms of all users. For instance, avatars designed to represent neurotypical Western interactions may not resonate with children from collectivist or non-Western cultures, potentially impairing therapeutic engagement or reinforcing cultural stereotypes (Parsons, 2016). Localization of therapeutic content and inclusion of cultural competency frameworks in software design are therefore essential to avoid alienation and ensure inclusivity.

Developmentally, interventions must be age-appropriate and neurodevelopmentally aligned, particularly given the heterogeneity of ASD trajectories. A critical risk involves over-reliance on automated systems that may lack sensitivity to fluctuating behavioral states or cognitive profiles. Younger children, for example, may require simplified user interfaces, constrained sensory input, and scaffolded task progression to avoid cognitive overload or frustration (Bauminger-Zvieli & Kugelmass, 2013). Moreover, longitudinal developmental impacts of extended screen-based exposure and immersive VR use remain understudied, prompting calls for age-specific usage guidelines grounded in developmental neuroscience (American Academy of Pediatrics, 2016).

Equity in access is also an ethical imperative. Socioeconomic disparities in digital literacy, device ownership, and broadband access can result in digital exclusion, exacerbating existing inequalities in ASD service delivery (Naslund et al., 2020). These disparities are particularly concerning in low- and middle-income countries, where access to in-person therapies is already limited and reliance on digital solutions is growing without parallel investment in infrastructure and training.

Addressing these ethical, cultural, and developmental dimensions requires the formation of interdisciplinary governance frameworks that incorporate the voices of clinicians, technologists, ethicists, and, critically, autistic individuals and their families. Transparent algorithmic design, culturally inclusive content, and evidence-based developmental thresholds should be codified as foundational principles in the next generation of digital ASD therapies.

Figure 5 outlines critical considerations for implementing digital therapeutics in Autism Spectrum Disorder (ASD). It emphasizes ethical concerns, developmental alignment, cultural relevance, and equitable access as foundational pillars for responsible and effective deployment. These factors ensure digital tools are inclusive, age-appropriate, secure, and accessible across diverse populations.



Fig 5 Ethical Considerations in Digital ASD Therapies

V. FUTURE DIRECTIONS AND CONCLUSION

➢ *Gaps in Current Research and Practice*

Although Digital Therapeutics (DTx) and Virtual Reality (VR) are increasingly recognized as innovative tools in the treatment of Autism Spectrum Disorder (ASD), current research still faces significant limitations that constrain their translation into standardized clinical practice. A primary gap is the lack of large-scale, multi-site randomized controlled trials (RCTs) validating the long-term efficacy and generalizability of these interventions. Most existing studies are limited by small sample sizes, homogeneous participant demographics, and short intervention durations, which limit the statistical power and ecological validity necessary for regulatory endorsement and broad clinical integration (Whitehouse et al., 2017; Kandalaft et al., 2013).

Furthermore, many DTx and VR-based studies employ non-standardized outcome measures, making meta-analytic comparisons and reproducibility challenging. Tools such as the Social Responsiveness Scale (SRS-2) or the Autism Diagnostic Observation Schedule (ADOS-2) are inconsistently applied, while some studies rely on unvalidated custom metrics or subjective clinician reports, which can introduce observer bias and reduce the reliability of treatment effects (Parsons, 2016). The absence of consensus-based digital biomarkers and objective computational endpoints impedes the development of closed-loop systems and the implementation of precision behavioral medicine frameworks (Insel, 2017).

A related concern is the underutilization of neurophysiological correlates—such as EEG, heart rate variability (HRV), and eye-tracking data—as adjuncts to behavioral assessments. Although such biosensors can enhance interpretability by linking observed behavior with underlying neural dynamics, their incorporation into clinical DTx and VR platforms remains sporadic, often confined to research prototypes without scalability (Ke & Im, 2013). This lack of multimodal integration hinders the development of adaptive, context-aware interventions necessary to accommodate ASD's heterogeneous symptomatology.

Additionally, developmental stage-specific adaptations are inadequately addressed. Many interventions fail to differentiate therapeutic content across age brackets, leading to mismatches in cognitive demands and user interface design. Adolescents with ASD, for example, often require contextually rich, peer-oriented simulations to address complex social narratives, while early childhood interventions may necessitate reduced sensory input and scaffolded progression (Bauminger-Zvieli & Kugelmass, 2013). Without developmental stratification, interventions risk reduced efficacy and poor generalization.

Finally, there is insufficient research on the implementation science and cost-effectiveness of these technologies in real-world clinical settings. Variables such as therapist training, infrastructure readiness, hardware durability, and reimbursement mechanisms are rarely evaluated in existing studies, leaving a translational gap between innovation and adoption (Naslund et al., 2020). This disconnect is particularly pronounced in underserved populations and low-resource regions where the digital divide further compounds access disparities.

- *Innovation Opportunities in ASD Digital Intervention*

Future innovation in digital interventions for Autism Spectrum Disorder (ASD) lies in the advancement of adaptive, intelligent systems capable of real-time personalization across cognitive, emotional, and behavioral domains. A primary area of development is the integration of artificial intelligence (AI) and deep learning architectures into both Digital Therapeutics (DTx) and Virtual Reality (VR) platforms to facilitate context-aware interventions that adjust dynamically based on user behavior, environmental stimuli, and biometric feedback (Insel, 2017; Topol, 2019). These AI-enhanced systems could utilize recurrent neural networks (RNNs) and reinforcement learning algorithms to fine-tune the difficulty and pacing of therapeutic modules, maximizing engagement and neuroplastic potential.

Another innovation opportunity lies in the incorporation of multimodal data fusion, wherein diverse input streams—such as electroencephalography (EEG), electrodermal activity (EDA), eye-tracking, and speech analytics—are synthesized to construct digital phenotypes for ASD individuals. This enables more granular tracking of emotional states and cognitive load, which can guide algorithmic decision-making in real time (Goodwin et al., 2019). For instance, a VR scenario might adaptively reduce sensory complexity if elevated arousal or attentional fatigue is detected through physiological monitoring.

The use of gamification frameworks and neurofeedback presents another promising frontier. Gamified DTx modules employing task-based rewards and narrative immersion can increase intrinsic motivation and session adherence, particularly in adolescents with ASD who show elevated preference for rule-based, visually dynamic systems (Khowaja et al., 2020). Coupling these frameworks with neurofeedback—e.g., providing users visualized feedback on their own neural activity—could enhance metacognitive awareness and facilitate volitional regulation of affective states.

Furthermore, cloud-based interoperability and telehealth integration can enhance access to high-quality digital care across geographic and socioeconomic divides. Secure cloud environments supporting Health Level Seven (HL7) and Fast Healthcare Interoperability Resources (FHIR) standards would enable seamless data exchange between DTx/VR platforms and electronic health records (EHRs), facilitating clinician oversight and continuity of care (Naslund et al., 2020). These architectures also allow for remote clinician calibration of intervention protocols based on back-end analytics, supporting hybrid care models.

Lastly, the development of open-source development frameworks and SDKs (Software Development Kits) tailored for ASD-specific applications can democratize innovation and foster collaborative design. Such platforms can accelerate the prototyping of culturally and developmentally appropriate interventions while ensuring alignment with privacy regulations such as HIPAA and GDPR (Parsons & Cobb, 2011). Community-driven development, supported by participatory design methodologies that include autistic individuals and caregivers, further ensures usability, accessibility, and clinical relevance.

- *Conclusion and Policy Implications*

The integration of Digital Therapeutics (DTx) and Virtual Reality (VR) into Autism Spectrum Disorder (ASD) interventions represents a paradigmatic shift in neurodevelopmental treatment, offering scalable, precision-oriented modalities that transcend the limitations of traditional therapy. These technologies capitalize on computational intelligence, real-time feedback systems, and multimodal sensory integration to deliver interventions that are both ecologically valid and neurocognitively aligned. When systematically engineered, DTx and VR can be fine-tuned to individual phenotypic and behavioral profiles, optimizing therapeutic yield across heterogeneous ASD presentations.

However, the clinical utility of these technologies remains constrained by several structural and translational challenges, including inadequate longitudinal validation, limited interoperability with health information systems, and disparities in digital access and literacy. Addressing these barriers demands not only technical innovation but also strategic policy frameworks that prioritize inclusivity, regulatory oversight, and cross-sector collaboration.

Policy directives should encourage the standardization of outcome measures, certification pathways for software-based interventions, and reimbursement models that recognize the clinical legitimacy of digital care. Additionally, cross-disciplinary regulatory bodies must be empowered to evaluate the safety, efficacy, and ethical compliance of AI-driven, immersive platforms—particularly in pediatric and neurodiverse populations.

Public investment in digital infrastructure, clinician training, and participatory design initiatives is essential to ensure that these technologies are equitably deployed and aligned with the lived realities of ASD individuals and their caregivers. National and international health agencies must also consider the integration of DTx and VR into existing care pathways, including early screening, school-based interventions, and community-based rehabilitation programs.

As digital health continues to evolve, the fusion of algorithmic precision, neurobiological insight, and immersive engagement holds the potential to redefine therapeutic norms in ASD. The realization of this potential will depend on sustained scientific rigor, inclusive policy frameworks, and ethical innovation that places the neurodiverse individual at the center of design and delivery.

REFERENCES (APA STYLE)

[1] American Academy of Pediatrics. (2016). Media and young minds. *Pediatrics*, 138(5), e20162591. https://doi.org/10.1542/peds.2016-2591

[2] Bauminger-Zvieli, N., & Kugelmass, D. (2013). Innovative technology-based interventions for social communication challenges in ASD: The role of developmental level. *Research in Autism Spectrum Disorders*, 7(9), 1101–1112. https://doi.org/10.1016/j.rasd.2013.05.015

[3] Goodwin, M. S., Velicer, M. D., Intille, S. S., & Albinali, F. (2019). Moving towards a real-time system for predicting social-emotional states in children with autism spectrum disorders using physiological sensors. *ACM Transactions on Interactive Intelligent Systems (TiiS)*, 9(2–3), 1–26. https://doi.org/10.1145/3340258

[4] Insel, T. R. (2017). Digital phenotyping: Technology for a new science of behavior. *JAMA*, 318(13), 1215–1216. https://doi.org/10.1001/jama.2017.11295

[5] Kandalaft, M. R., Didehbani, N., Krawczyk, D. C., Allen, T. T., & Chapman, S. B. (2013). Virtual reality social cognition training for young adults with high-functioning autism. *Journal of Autism and Developmental Disorders*, 43(1), 34–44. https://doi.org/10.1007/s10803-012-1544-6

[6] Ke, F., & Im, T. (2013). Virtual-reality-based social interaction training for children with high-functioning autism. *Journal of Educational Research*, 106(6), 441–461. https://doi.org/10.1080/00220671.2013.832999

[7] Keshav, N. U., Salisbury, J. P., Vahabzadeh, A., & Sahin, N. T. (2017). Social communication coaching smartglasses: Well tolerated in a diverse sample of children and adults with autism. *JMIR mHealth and uHealth*, 5(9), e140. https://doi.org/10.2196/mhealth.8534

[8] Khowaja, K., Salim, S. S., Asemi, A., Alfarraj, O., & Aldalbahi, A. (2020). Therapeutic applications of virtual reality in autism spectrum disorder: A systematic review. *International Journal of Environmental Research and Public Health*, 17(17), 6114. https://doi.org/10.3390/ijerph17176114

[9] Lorenzo, G., Lledó, A., Pomares, J., & Roig, R. (2016). Design and application of an immersive virtual reality system to enhance emotional skills for children with autism spectrum disorders. *Computers in Human Behavior*, 55, 182–195. https://doi.org/10.1016/j.chb.2015.09.033

[10] Miller, H. L., & Bugnariu, N. L. (2016). Level of immersion in virtual environments impacts the ability to assess and teach social skills in autism spectrum disorder. *Cyberpsychology, Behavior, and Social Networking*, 19(4), 246–256. https://doi.org/10.1089/cyber.2015.0401

[11] Naslund, J. A., Aschbrenner, K. A., Araya, R., Marsch, L. A., Unützer, J., Patel, V., & Bartels, S. J. (2020). Digital technology for treating and preventing mental disorders in low-income and middle-income countries: A narrative review of the literature. *The Lancet Psychiatry*, 7(6), 487–500. https://doi.org/10.1016/S2215-0366(20)30069-1

[12] Parsons, S. (2016). Authenticity in virtual reality for assessment and intervention in autism: A conceptual review. *Educational Research Review*, 19, 138–157. https://doi.org/10.1016/j.edurev.2016.08.001

[13] Parsons, S., & Cobb, S. (2011). State-of-the-art of virtual reality technologies for children on the autism spectrum. *European Journal of Special Needs Education*, 26(3), 355–366. https://doi.org/10.1080/08856257.2011.593831

[14] Raspa, M., Toth, D., Ludlow, L., Nelson, R., Moultrie, R., & Baranek, G. (2020). Barriers and facilitators to using digital therapeutics to support social-emotional development in children with neurodevelopmental disorders. *Journal of Developmental & Behavioral Pediatrics*, 41(6), 440–451. https://doi.org/10.1097/DBP.0000000000000813

[15] Topol, E. (2019). *Deep medicine: How artificial intelligence can make healthcare human again*. New York, NY: Basic Books.

[16] Torous, J., Bucci, S., Bell, I. H., Kessing, L. V., Faurholt-Jepsen, M., Whelan, P., ... & Firth, J. (2019). The growing field of digital psychiatry: Current evidence and the future of apps, social media, chatbots, and virtual reality. *World Psychiatry*, 18(3), 318–335. https://doi.org/10.1002/wps.20672

[17] Whitehouse, A. J. O., Granich, J., Alvares, G., Busacca, M., Cooper, M. N., Dass, A., ... & Dixon, G. (2017). A randomised controlled trial of an iPad-based application to complement early behavioural intervention in Autism Spectrum Disorder. *Journal of Child Psychology and Psychiatry*, 58(9), 1042–1052. https://doi.org/10.1111/jcpp.12754
[18] Zhao, Y., Xu, H., & Zhang, Y. (2021). Reinforcement learning for adaptive intervention in digital health: A review. *Health Informatics Journal*, 27(1), 1460458221994853. https://doi.org/10.1177/1460458221994853